Newer β-Lactam/β-Lactamase inhibitor for multidrug-resistant gram-negative infections: Challenges, implications and surveillance strategy for India

Indian Journal of Medical Microbiology

Volumn 36, Issue 3, 2018, Pages 334-343

  Veeraraghavan, Balaji ^a   Pragasam, Agila ^a   Bakthavatchalam, Yamuna ^a   Anandan, Shalini ^a   Ramasubramanian, V ^b   Swaminathan, Subramanian ^c   Gopalakrishnan, Ram ^b   Soman, Rajeev ^d   Abraham, O ^e   Ohri, Vinod ^f   Walia, Kamini ^f  

^a Department of Clinical Microbiology ^*  (India)

^b Apollo Hospital   (India)

^c Global Hospitals   (India)

^d P D HINDUJA NATIONAL HOSPITAL   (India)

^e CHRISTIAN MEDICAL COLLEGE   (India)

^f INDIAN COUNCIL OF MEDICAL RESEARCH   (India)

Author keywords

Antimicrobial resistance; carbapenemase; India; newer beta lactam beta lactamase inhibitor; surveillance

Indexed keywords

AVIBACTAM PLUS CEFTAZIDIME; AZTREONAM; BETA LACTAM; BETA LACTAMASE INHIBITOR; CARBAPENEM; CARBAPENEMASE; CEFOPERAZONE PLUS SULBACTAM; CEFTOLOZANE PLUS TAZOBACTAM; CEPHALOSPORIN; IMIPENEM; MEROPENEM PLUS VABORBACTAM; PIPERACILLIN; RELEBACTAM; RNA 16S; TAZOBACTAM; ANTIINFECTIVE AGENT;

ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL STEWARDSHIP; ARTICLE; BROTH DILUTION; DISEASE SURVEILLANCE; DISK DIFFUSION; ENHANCER REGION; ENTEROBACTERIACEAE; ESCHERICHIA COLI; GENE DOSAGE; GENE MUTATION; GENOTYPE; GRAM NEGATIVE INFECTION; HOSPITAL INFECTION; HUMAN; INDIA; INFECTION CONTROL; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR EPIDEMIOLOGY; MOLECULARLY TARGETED THERAPY; MULTIDRUG RESISTANCE; PATIENT CARE; PHENOTYPE; PREVALENCE; PSEUDOMONAS AERUGINOSA; BACTERIAL GENE; CLASSIFICATION; COMBINATION DRUG THERAPY; DRUG EFFECT; EPIDEMIOLOGICAL MONITORING; GENETICS; GRAM NEGATIVE BACTERIUM; MICROBIOLOGY;

ANTI-BACTERIAL AGENTS; BETA-LACTAMASE INHIBITORS; BETA-LACTAMS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG THERAPY, COMBINATION; EPIDEMIOLOGICAL MONITORING; GENES, BACTERIAL; GENOTYPE; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; INDIA; MOLECULAR EPIDEMIOLOGY;

EID: 85056627305     PISSN: 02550857     EISSN: 19983646     Source Type: Journal    
DOI: 10.4103/ijmm.IJMM_18_326     Document Type: Article

References (67)

1. Worthington RJ, Melander C. Overcoming resistance to βlactam antibiotics. J Org Chem 2013;78:4207-13.
2. Bonomo RA. βlactamases: A Focus on current challenges. Cold Spring Harb Perspect Med 2017;7. pii: A025239.
3. Sullivan R, Schaus D, John M, Delport JA. Extended spectrum beta-lactamases: A mini review of clinical relevant groups. J Med Microbiol Diagn 2015;4:2161-0703.
4. Ur Rahman S, Ali T, Ali I, Khan NA, Han B, Gao J, et al. The growing genetic and functional diversity of extended spectrum beta-lactamases. Biomed Res Int 2018;2018:9519718.
5. Partridge SR, Kwong SM, Firth N, Jensen SO. Mobile genetic elements associated with antimicrobial resistance. Clin Microbiol Rev 2018;31. pii: e00088-17.
6. van Hoek AH, Mevius D, Guerra B, Mullany P, Roberts AP, Aarts HJ, et al. Acquired antibiotic resistance genes: An overview. Front Microbiol 2011;2:203.
7. El Salabi A, Walsh TR, Chouchani C. Extended spectrum βlactamases, carbapenemases and mobile genetic elements responsible for antibiotics resistance in gram-negative bacteria. Crit Rev Microbiol 2013;39:113-22.
8. Drawz SM, Bonomo RA. Three decades of beta-lactamase inhibitors. Clin Microbiol Rev 2010;23:160-201.
9. Bush K, Bradford PA. βlactams and βlactamase inhibitors: An overview. Cold Spring Harb Perspect Med 2016;6. pii: A025247.
10. Papp-Wallace KM, Bonomo RA. New βlactamase inhibitors in the clinic. Infect Dis Clin North Am 2016;30:441-64.
11. Gandra S, Joshi J, Trett A, Sankhil LA. Scoping Report on Antimicrobial Resistance in India. Washington, DC: Center for Disease Dynamics, Economics & Policy; 2017.
12. Gandra S, Singh SK, Jinka DR, Kanithi R, Chikkappa AK, Sharma A, et al. Point prevalence surveys of antimicrobial use among hospitalized children in six hospitals in India in 2016. Antibiotics (Basel) 2017;6. pii: E19.
13. Shankar C, Veeraraghavan B, Nabarro LEB, Ravi R, Ragupathi NKD, Rupali P, et al. Whole genome analysis of hypervirulent Klebsiella pneumoniae isolates from community and hospital acquired bloodstream infection. BMC Microbiol 2018;18:6.
14. Abi M, Chaitra S, Nabarro L, George MV, Balaji V. Hypervirulent, regulator of mucoid phenotype A positive Klebsiella pneumoniae liver abscess. J Glob Infect Dis 2018;10:30-1.
15. Pragasam AK, Shankar C, Veeraraghavan B, Biswas I, Nabarro LE, Inbanathan FY, et al. Molecular mechanisms of colistin resistance in Klebsiella pneumoniae causing bacteremia from India-A first report. Front Microbiol 2016;7:2135.
16. Pragasam AK, Vijayakumar S, Bakthavatchalam YD, Kapil A, Das BK, Ray P, et al. Molecular characterisation of antimicrobial resistance in Pseudomonas aeruginosa and Acinetobacter baumannii during 2014 and 2015 collected across India. Indian J Med Microbiol 2016;34:433-41.
17. Devanga Ragupathi NK, Bakthavatchalam YD, Mathur P, Pragasam AK, Walia K, Ohri VC, et al. Plasmid profiles among some ESKAPE pathogens in South India: A Next generation sequencing approach. Indian J Med Res 2018. (In Press).
18. Vijayakumar S, Mathur P, Kapil A, Bimal KD, Ray P, Gautham V, et al. Molecular characterization and epidemiology of Carbapenem-resistant Acinetobacter baumannii collected across India. Indian J Med Res. (In Press).
19. Shankar C, Venkatesan M, Rajan R, Mani D, Lal B, Prakash JA, et al. Molecular characterization of colistin resistant Klebsiella pneumoniae and its clonal relationship among South Indian isolates. 2018 Indian J Med Res. (In Press).
20. Paterson DL, Bonomo RA. Extended-spectrum beta-lactamases: A clinical update. Clin Microbiol Rev 2005;18:657-86.
21. Rawat D, Nair D. Extended-spectrum βlactamases in gram negative bacteria. J Glob Infect Dis 2010;2:263-74.
22. Clinical and Laboratory Standards Institute Performance Standards for Antimicrobial Susceptibility Testing; Twentieth Informational Supplements. Document M100-S20. Wayne, PA: CLSI; 2010.
23. Livermore DM, Andrews JM, Hawkey PM, Ho PL, Keness Y, Doi Y, et al. Are susceptibility tests enough, or should laboratories still seek ESBLs and carbapenemases directly J Antimicrob Chemother 2012;67:1569-77.
24. Schuetz AN, Reyes S, Tamma PD. Point-counterpoint: Piperacillin-tazobactam should be used to treat infections with extended-spectrum-beta-lactamase-positive organisms. J Clin Microbiol 2018;56. pii: e01917-17.
25. Harris PN, Peleg AY, Iredell J, Ingram PR, Miyakis S, Stewardson AJ, et al. Meropenem versus piperacillin-tazobactam for definitive treatment of bloodstream infections due to ceftriaxone non-susceptible Escherichia coli and Klebsiella spp (the MERINO trial): Study protocol for a randomised controlled trial. Trials 2015;16:24.
26. Craig WA. Does the dose matter Clin Infect Dis 2001;33 Suppl 3:S233-7.
27. Kazmierczak KM, de Jonge BLM, Stone GG, Sahm DF. In vitro activity of ceftazidime/avibactam against isolates of Pseudomonas aeruginosa collected in European countries: INFORM global surveillance 2012-15. J Antimicrob Chemother 2018;73:2777-81. doi: 10. 1093/jac/dky267.
28. Yu F, Lv J, Niu S, Du H, Tang YW, Bonomo RA, et al. In vitro activity of ceftazidime-avibactam against carbapenem-resistant and hypervirulent Klebsiella pneumoniae isolates. Antimicrob Agents Chemother 2018;62. pii: e01031-18.
29. Stewart A, Harris P, Henderson A, Paterson D. Treatment of infections with OXA-48 producing Enterobacteriaceae. Antimicrob Agents Chemother 2018. pii: AAC. 01195-18.
30. Both A, Büttner H, Huang J, Perbandt M, Belmar Campos C, Christner M, et al. Emergence of ceftazidime/avibactam non-susceptibility in an MDR Klebsiella pneumoniae isolate. J Antimicrob Chemother 2017;72:2483-8.
31. Haidar G, Clancy CJ, Chen L, Samanta P, Shields RK, Kreiswirth BN, et al. Identifying spectra of activity and therapeutic niches for ceftazidime-avibactam and imipenem-relebactam against carbapenem-resistant Enterobacteriaceae. Antimicrob Agents Chemother 2017;61. pii: e00642-17.
32. Nicolas-Chanoine MH, Mayer N, Guyot K, Dumont E, Pagès JM. Interplay between membrane permeability and enzymatic barrier leads to antibiotic-dependent resistance in Klebsiella pneumoniae. Front Microbiol 2018;9:1422.
33. Nguyen L, Garcia J, Gruenberg K, MacDougall C. Multidrug-resistant pseudomonas infections: Hard to treat, but hope on the horizon Curr Infect Dis Rep 2018;20:23.
34. Shortridge D, Pfaller MA, Castanheira M, Flamm RK. Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa collected from patients with bloodstream infections isolated in United States hospitals (2013-2015) as part of the program to assess ceftolozane-tazobactam susceptibility (PACTS) surveillance program. Diagn Microbiol Infect Dis 2018;92:158-63.
35. Plant AJ, Dunn A, Porter RJ. Ceftolozane-tazobactam resistance induced in vivo during the treatment of MDR Pseudomonas aeruginosa pneumonia. Expert Rev Anti Infect Ther 2018;16:367-8.
36. Rodríguez-Baño J, Gutiérrez-Gutiérrez B, Machuca I, Pascual A. Treatment of infections caused by extended-spectrum-beta-lactamase-, ampC-, and carbapenemase-producing Enterobacteriaceae. Clin Microbiol Rev 2018;31. pii: e00079-17.
37. Sun D, Rubio-Aparicio D, Nelson K, Dudley MN, Lomovskaya O. Meropenem-vaborbactam resistance selection, resistance prevention, and molecular mechanisms in mutants of KPC-producing Klebsiella pneumoniae. Antimicrob Agents Chemother 2017;61.
38. Vasoo S, Cunningham SA, Cole NC, Kohner PC, Menon SR, Krause KM, et al. In vitro activities of ceftazidime-avibactam, aztreonam-avibactam, and a panel of older and contemporary antimicrobial agents against carbapenemase-producing gram-negative bacilli. Antimicrob Agents Chemother 2015;59:7842-6.
39. Wiskirchen DE, Crandon JL, Nicolau DP. Impact of various conditions on the efficacy of dual carbapenem therapy against KPC-producing Klebsiella pneumoniae. Int J Antimicrob Agents 2013;41:582-5.
40. Sader HS, Mendes RE, Pfaller MA, Shortridge D, Flamm RK, Castanheira M, et al. Antimicrobial activities of aztreonam-avibactam and comparator agents against contemporary (2016) clinical Enterobacteriaceae isolates. Antimicrob Agents Chemother 2018;62. pii: e01856-17.
41. Bakthavatchalam YD, Anandan S, Veeraraghavan B. Laboratory detection and clinical implication of oxacillinase-48 like carbapenemase: The hidden threat. J Glob Infect Dis 2016;8:41-50.
42. Turton JF, Doumith M, Hopkins KL, Perry C, Meunier D, Woodford N, et al. Clonal expansion of Escherichia coli ST38 carrying a chromosomally integrated OXA-48 carbapenemase gene. J Med Microbiol 2016;65:538-46.
43. Chew KL, Tay MK, Cheng B, Lin RT, Octavia S, Teo JW, et al. Aztreonam-avibactam combination restores susceptibility of aztreonam in dual-carbapenemase-producing Enterobacteriaceae. Antimicrob Agents Chemother 2018;62. pii: e00414-18.
44. Lob SH, Hackel MA, Kazmierczak KM, Hoban DJ, Young K, Motyl MR, et al. In vitro activity of imipenem-relebactam against gram-negative bacilli isolated from patients with lower respiratory tract infections in the United States in 2015-Results from the SMART global surveillance program. Diagn Microbiol Infect Dis 2017;88:171-6.
45. Papp-Wallace KM, Barnes MD, Alsop J, Taracila MA, Bethel CR, Becka SA, et al. Relebactam is a potent inhibitor of the KPC-2 βlactamase and restores imipenem susceptibility in KPC-producing Enterobacteriaceae. Antimicrob Agents Chemother 2018;62. pii: e00174-18.
46. Gomez-Simmonds A, Stump S, Giddins MJ, Annavajhala MK, Uhlemann AC. Clonal background, resistance gene profile, and Porin gene mutations modulate In vitro susceptibility to imipenem-relebactam in diverse Enterobacteriaceae. Antimicrob Agents Chemother 2018;62. pii: e00573-18.
47. Zhanel GG, Lawrence CK, Adam H, Schweizer F, Zelenitsky S, Zhanel M, et al. Imipenem-relebactam and meropenem-vaborbactam: Two novel carbapenem-βlactamase inhibitor combinations. Drugs 2018;78:65-98.
48. National Policy for Containment of Antimicrobial Resistance. India. Directorate General of Health Services; 2011. Available from: https:// onlinedruginfo. punjab. gov. in/pdf/national-policy-for-containment- of-antimicrobial-resistance. pdf. [Last accessed on 2018 Sep 09].
49. Indian Council of Medical Research. Annual Report 2012-13. Indian Council of Medical Research; 2013. Available from: https://www. icmr. nic. in/sites/default/files/annual-repoorts/Annual-Report-2012-2013- Indian-Council-of-Medical-Research-Delhi-English. pdf. [Last accessed on 2018 Sep 09].
50. National Action Plan on Antimicrobial Resistance. Government of India; April, 2017. Available from: http://www. searo. who. int/entity/ india/topics/antimicrobial-resistance/nap-amr. pdf. [Last accessed on 2018 Sep 09].
51. Hawkey PM, Warren RE, Livermore DM, McNulty CA, Enoch DA, Otter JA, et al. Treatment of infections caused by multidrug-resistant gram-negative bacteria: Report of the British Society for Antimicrobial Chemotherapy/Healthcare Infection Society/British Infection Association Joint Working Party. J Antimicrob Chemother 2018;73:iii2-78.
52. Gutiérrez-Gutiérrez B, Pérez-Galera S, Salamanca E, de Cueto M, Calbo E, Almirante B, et al. A multinational, preregistered cohort study of βlactam/βlactamase inhibitor combinations for treatment of bloodstream infections due to extended-spectrum-βlactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother 2016;60:4159-69.
53. Corbella X, Ariza J, Ardanuy C, Vuelta M, Tubau F, Sora M, et al. Efficacy of sulbactam alone and in combination with ampicillin in nosocomial infections caused by multiresistant Acinetobacter baumannii. J Antimicrob Chemother 1998;42:793-802.
54. Chalhoub H, Tunney M, Elborn JS, Vergison A, Denis O, Plésiat P, et al. Avibactam confers susceptibility to a large proportion of ceftazidime-resistant Pseudomonas aeruginosa isolates recovered from cystic fibrosis patients. J Antimicrob Chemother 2015;70:1596-8.
55. Crandon JL, Schuck VJ, Banevicius MA, Beaudoin ME, Nichols WW, Tanudra MA, et al. Comparative in vitro and in vivo efficacies of human simulated doses of ceftazidime and ceftazidime-avibactam against Pseudomonas aeruginosa. Antimicrob Agents Chemother 2012;56:6137-46.
56. Sader HS, Castanheira M, Mendes RE, Flamm RK, Farrell DJ, Jones RN, et al. Ceftazidime-avibactam activity against multidrug-resistant Pseudomonas aeruginosa isolated in U. S. Medical centers in 2012 and 2013. Antimicrob Agents Chemother 2015;59:3656-9.
57. Flamm RK, Farrell DJ, Sader HS, Jones RN. Ceftazidime/avibactam activity tested against gram-negative bacteria isolated from bloodstream, pneumonia, intra-abdominal and urinary tract infections in US medical centres (2012). J Antimicrob Chemother 2014;69:1589-98.
58. Coleman K, Levasseur P, Girard AM, Borgonovi M, Miossec C, Merdjan H, et al. Activities of ceftazidime and avibactam against βlactamase-producing Enterobacteriaceae in a hollow-fiber pharmacodynamic model. Antimicrob Agents Chemother 2014;58:3366-72.
59. Farrell DJ, Flamm RK, Sader HS, Jones RN. Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in U. S. Hospitals (2011-2012). Antimicrob Agents Chemother 2013;57:6305-10.
60. Shields RK, Clancy CJ, Hao B, Chen L, Press EG, Iovine NM, et al. Effects of Klebsiella pneumoniae carbapenemase subtypes, extended-spectrum βlactamases, and porin mutations on the in vitro activity of ceftazidime-avibactam against carbapenem-resistant K. pneumoniae. Antimicrob Agents Chemother 2015;59:5793-7.
61. CDC. Carbapenem Resistant Enterobacteriaceae; 2016. Available from: https://wwwn. cdc. gov/nndss/conditions/carbapenemase-producingcarbapenem-resistant-enterobacteriaceae/case-definition/2018/. [Last accessed on 2018 Sep 09].
62. Cantón R, Akóva M, Carmeli Y, Giske CG, Glupczynski Y, Gniadkowski M, et al. Rapid evolution and spread of carbapenemases among Enterobacteriaceae in Europe. Clin Microbiol Infect 2012;18:413-31.
63. Nordmann P, Naas T, Poirel L. Global spread of carbapenemase-producing Enterobacteriaceae. Emerg Infect Dis 2011;17:1791-8.
64. Gupta N, Limbago BM, Patel JB, Kallen AJ. Carbapenem-resistant Enterobacteriaceae: Epidemiology and prevention. Clin Infect Dis 2011;53:60-7.
65. Lapuebla A, Abdallah M, Olafisoye O, Cortes C, Urban C, Quale J, et al. Activity of meropenem combined with RPX7009, a novel beta-lactamase inhibitor, against Gramnegative clinical isolates in New York city. Antimicrob Agents Chemother 2015;59:4856-60.
66. Petty NK, Ben Zakour NL, Stanton-Cook M, Skippington E, Totsika M, Forde BM, et al. Global dissemination of a multidrug resistant Escherichia coli clone. Proc Natl Acad Sci U S A 2014;111:5694-9.
67. Potz NA, Hope R, Warner M, Johnson AP, Livermore DM; London and South East ESBL Project Group. et al. Prevalence and mechanisms of cephalosporin resistance in Enterobacteriaceae in London and South-East England. J Antimicrob Chemother 2006;58:320-6.